<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC1A2 — Solute Carrier Family 1 Member 2 (EAAT2)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SLC1A2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SLC1A2 — Solute Carrier Family 1 Member 2 (EAAT2)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=SLC1A2" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/adhd" style="color:#ef9a9a">ADHD</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a>, <a href="/wiki/fragile-x-syndrome" style="color:#ef9a9a">Fragile X Syndrome</a>, <a href="/wiki/frontotemporal-dementia" style="color:#ef9a9a">Frontotemporal Dementia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">32 edges</a></td>
</tr>
</table>
SLC1A2 (Solute Carrier Family 1 Member 2), also known as EAAT2 (Excitatory Amino Acid Transporter 2) or GLT-1 (Glutamate Transporter 1), is the predominant glutamate transporter in the central nervous system. It is responsible for the vast majority of glutamate reuptake from the synaptic cleft, maintaining glutamate concentrations at non-toxic levels and preventing excitotoxicity. SLC1A2 is expressed primarily in astrocytes surrounding synapses, where it plays a critical role in synaptic homeostasis and neuroprotection.
Glutamate is the major excitatory neurotransmitter in the brain, but excessive glutamate accumulation leads to overactivation of NMDA and AMPA receptors, triggering calcium influx, oxidative stress, and ultimately neuronal death. SLC1A2 is therefore essential for neuronal survival, and its dysfunction is implicated in multiple neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
The SLC1A2 gene is located on chromosome 11p13 and consists of 19 exons spanning approximately 43 kilobases. The gene encodes a protein of 574 amino acids with a molecular weight of approximately 66 kDa. SLC1A2 belongs to the excitatory amino acid transporter (EAAT) family, which includes five related transporters (EAAT1-5).
SLC1A2 is expressed predominantly in the brain, with highest levels in:
SLC1A2 is a transmembrane protein with eight to ten transmembrane domains. The transporter operates as a stoichiometric symporter, importing one glutamate molecule together with three sodium ions and one proton, while counter-transporting one potassium ion. This electrogenic process creates a substantial inward current that can be measured electrophysiologically.
Under normal physiological conditions, SLC1A2 clears approximately 80-90% of synaptic glutamate. After glutamate release from presynaptic neurons and activation of postsynaptic receptors, SLC1A2 rapidly transports glutamate into astrocytes, where it is converted to glutamine by glutamine synthetase and returned to neurons for recycling.
The kinetics of SLC1A2 are remarkable:
SLC1A2-mediated glutamate uptake is tightly coupled to astrocyte metabolism. Astrocytes convert internalized glutamate to glutamine, which is then released and taken up by neurons. This cycle, known as the glutamate-glutamine cycle, is essential for:
Excitotoxicity is a pathological process whereby excessive glutamate receptor activation leads to neuronal death. SLC1A2 dysfunction contributes to excitotoxicity through multiple mechanisms:
Multiple lines of evidence implicate SLC1A2 dysfunction in AD:
In PD, SLC1A2 dysfunction contributes to dopaminergic neuron vulnerability:
ALS shows the strongest association with SLC1A2 dysfunction:
Several common polymorphisms in SLC1A2 have been studied in neurodegenerative diseases:
Rare loss-of-function variants in SLC1A2 have been identified in:
Given the critical role of SLC1A2 in preventing excitotoxicity, enhancing its function is a major therapeutic goal:
Ceftriaxone: This antibiotic was shown in preclinical studies to upregulate SLC1A2 expression and increase glutamate uptake. Although ceftriaxone failed in ALS clinical trials (possibly due to inadequate brain penetration), it validated SLC1A2 as a therapeutic target.
β-lactam antibiotics: Related antibiotics with better blood-brain barrier penetration are being investigated.
Riluzole: While primarily acting on presynaptic glutamate release, riluzole may also enhance astrocyte glutamate uptake.
AAV-mediated delivery of SLC1A2 to astrocytes is being explored for ALS and other conditions. Preclinical studies have shown that increased SLC1A2 expression protects motor neurons from excitotoxic death.
High-throughput screening has identified small molecules that directly activate SLC1A2, though none have reached clinical trials yet.
SLC1A2 connects to several key neurodegenerative pathways:
SLC1A2 (EAAT2/GLT-1) is the primary glutamate transporter in the brain, responsible for clearing synaptic glutamate and preventing excitotoxic neuronal death. Its dysfunction is strongly implicated in Alzheimer's disease, Parkinson's disease, and ALS. Genetic variants and acquired dysfunction of SLC1A2 contribute to disease pathogenesis through reduced glutamate clearance, enhanced NMDA receptor activation, and subsequent calcium-dependent neuronal injury. Enhancing SLC1A2 function represents a promising therapeutic strategy for multiple neurodegenerative conditions.
The following diagram shows the key molecular relationships involving SLC1A2 — Solute Carrier Family 1 Member 2 (EAAT2) discovered through SciDEX knowledge graph analysis: